Vident Advisory’s Medifast MED Stock Holding History

Vident Advisory’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,965	Closed	-$267K	–	1373
2023 Q4	$267K	Sell	3,965 -122	-3%	-$8.5K	0.01%	1053
2023 Q3	$306K	Buy	+4,087	New	+$363K	0.01%	888

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Vident Advisory's MED Position: Q1 2024 in Review

Vident Advisory sold out of Medifast (MED) in Q1 2024, closing a stake of 3,965 shares — an estimated $267K sold.

Vident Advisory first reported a position in MED in Q3 2023 and held it in 2 quarters. The position peaked at $306K in Q3 2023. 186 funds tracked by Wall St. Rank hold MED as of Q1 2024.

Vident Advisory reported no remaining Medifast position as of Q1 2024 after selling out during the quarter.
Vident Advisory sold 3,965 Medifast shares in Q1 2024, an estimated $267K.
Vident Advisory first reported a position in Medifast in Q3 2023 and held it in 2 quarters.
Vident Advisory's Medifast position peaked at $306K in Q3 2023.
186 funds tracked by Wall St. Rank held Medifast as of Q1 2024.

Based on Vident Advisory's 13F filing for Q1 2024, filed 14 May 2024.